This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Hologic (HOLX) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Hologic (HOLX) closed at $69.95, marking a -1.99% move from the previous day.
Hologic (HOLX) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Hologic (HOLX) closed at $70.31, marking a -0.55% move from the previous day.
Hologic (HOLX) Adds New Products to Omni Hysteroscopy Offering
by Zacks Equity Research
Hologic (HOLX) expands Omni suite in EMEA with the new Omni 30 degree hysteroscope, Omni Lok cervical seal and Omni 5 French seal products.
Hologic (HOLX) Stock Moves -1.57%: What You Should Know
by Zacks Equity Research
Hologic (HOLX) closed at $72.87 in the latest trading session, marking a -1.57% move from the prior day.
Hologic (HOLX) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Hologic (HOLX) closed at $76.44 in the latest trading session, marking a -0.38% move from the prior day.
Hologic (HOLX) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Hologic (HOLX) closed the most recent trading day at $77.62, moving -0.55% from the previous trading session.
Hologic (HOLX) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Hologic (HOLX) closed the most recent trading day at $79.95, moving -0.98% from the previous trading session.
Hologic (HOLX) Up 5.7% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Hologic (HOLX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Hologic (HOLX) Acessa Procedure Gets Anthem Insurance Coverage
by Zacks Equity Research
Hologic's (HOLX) Acessa Procedure's new coverage upholds Laparoscopic Radiofrequency Ablation for women suffering from uterine fibroids.
Hologic's (HOLX) Q3 Earnings Top Estimates, Q4 View Dull
by Zacks Equity Research
Impressive performance by the Breast Health and GYN Surgical segments drive Hologic's (HOLX) fiscal third-quarter revenues.
Hologic (HOLX) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Hologic (HOLX) delivered earnings and revenue surprises of 19.82% and 12.95%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Medical Device Stocks' Earnings on Jul 28: TMO, ALGN & More
by Urmimala Biswas
The sector's Q2 results are likely to reflect solid earnings and revenue growth on strong base business recovery.
Breast Health Sales to Aid Hologic's (HOLX) Q3 Earnings
by Zacks Equity Research
The acquisition of Biotheranostics and relaunch of Brevera are expected to have contributed to Hologic's (HOLX) Breast Health arm performance in the third quarter.
Hologic (HOLX) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Hologic's (HOLX) recent acquisitions and product launches are expected to contribute significantly to its third-quarter performance.
Hologic (HOLX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Hologic (HOLX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Hologic (HOLX) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Hologic (HOLX) closed at $70.37 in the latest trading session, marking a +1.19% move from the prior day.
What's in Store for Intuitive Surgical's (ISRG) Q2 Earnings?
by Zacks Equity Research
Intuitive Surgical's (ISRG) second-quarter results are likely to reflect solid performance at Instruments & Accessories segment.
Hologic (HOLX) COVID Test With Saliva Sample Gets CE Mark
by Zacks Equity Research
Per Hologic (HOLX), saliva collection is noninvasive and painless. The availability of this alternative specimen type should facilitate screening at schools, workplaces and other settings.
Hologic (HOLX) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Hologic (HOLX) closed the most recent trading day at $68.65, moving -0.77% from the previous trading session.
Hologic (HOLX) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Hologic (HOLX) closed at $69.64 in the latest trading session, marking a +0.9% move from the prior day.
Hologic (HOLX) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Hologic (HOLX) closed at $67.99 in the latest trading session, marking a +1.9% move from the prior day.
Here's How Much You'd Have If You Invested $1000 in Hologic a Decade Ago
by Zacks Equity Research
Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.
Hologic (HOLX) Gets European Nod for Aptima CMV Quant Assay
by Zacks Equity Research
Hologic's (HOLX) Aptima CMV Quant assay is intended to help in the diagnosis and management of solid-organ transplant patients and hematopoietic stem cell transplant patients.
Hologic (HOLX) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Hologic (HOLX) closed at $64.47 in the latest trading session, marking a +0.7% move from the prior day.
Hologic (HOLX) to Beat Post-COVID Woes With Mobidiag Buyout
by Zacks Equity Research
Hologic (HOLX) management believes that Mobidiag has created a differentiated platform that deals with many of the historical challenges faced in multiplexed point-of-care molecular testing.